Compile Data Set for Download or QSAR
Report error Found 57 Enz. Inhib. hit(s) with all data for entry = 11865
TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655514(US11912714, Example 11)
Affinity DataEC50:  550nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655509(US11912714, Example 6)
Affinity DataEC50: <100nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655508(US11912714, Example 5)
Affinity DataEC50: <100nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655506(US11912714, Example 4 | US11912714, Example 3)
Affinity DataEC50: <100nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655506(US11912714, Example 4 | US11912714, Example 3)
Affinity DataEC50:  550nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655505(US11912714, Example 2)
Affinity DataEC50:  550nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655504(US11912714, Example 1)
Affinity DataEC50: <100nMAssay Description:384-well black cell-culture-treated plastic clear-bottom plates are used in this assay. Using an ECHO liquid dispenser, 3-fold serial dilutions of co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655543(US11912714, Example 40)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655533(US11912714, Example 30)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655542(US11912714, Example 39)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655541(US11912714, Example 38)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655540(US11912714, Example 37)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655538(US11912714, Example 35)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655537(US11912714, Example 34)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655536(US11912714, Example 33)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655535(US11912714, Example 32)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655534(US11912714, Example 31)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655532(US11912714, Example 29)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655544(US11912714, Example 41)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655545(US11912714, Example 42)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655546(US11912714, Example 43)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655547(US11912714, Example 44)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655548(US11912714, Example 45)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655549(US11912714, Example 46)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655550(US11912714, Example 47)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655551(US11912714, Example 48)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655552(US11912714, Example 50 | US11912714, Example 49)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655552(US11912714, Example 50 | US11912714, Example 49)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655519(US11912714, Example 16)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655505(US11912714, Example 2)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655506(US11912714, Example 4 | US11912714, Example 3)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655506(US11912714, Example 4 | US11912714, Example 3)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655508(US11912714, Example 5)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655509(US11912714, Example 6)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655513(US11912714, Example 10)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655514(US11912714, Example 11)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655515(US11912714, Example 12)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655516(US11912714, Example 13)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655517(US11912714, Example 14)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655518(US11912714, Example 15)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655504(US11912714, Example 1)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655520(US11912714, Example 17)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655521(US11912714, Example 18)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655522(US11912714, Example 19)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655524(US11912714, Example 21)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655525(US11912714, Example 22)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655526(US11912714, Example 23)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655527(US11912714, Example 24)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655528(US11912714, Example 25)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM655529(US11912714, Example 26)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 57 total ) | Next | Last >>
Jump to: